Latest Developments in Engineered Skeletal Muscle Tissues for Drug Discovery and Development
dc.authorid | Fujie, Toshinori/0000-0003-1417-8670 | |
dc.authorid | Kaji, Hirokazu/0000-0003-2566-4172 | |
dc.authorid | Ramalingam, Murugan/0000-0001-6498-9792 | |
dc.authorid | ostrovidov, serge/0000-0002-4189-8086 | |
dc.authorid | bae, hojae/0000-0003-3057-4999 | |
dc.authorscopusid | 6602776344 | |
dc.authorscopusid | 59176479500 | |
dc.authorscopusid | 35799555800 | |
dc.authorscopusid | 6602772615 | |
dc.authorscopusid | 12801720000 | |
dc.authorscopusid | 55617444400 | |
dc.authorscopusid | 55617444400 | |
dc.authorwosid | Shi, Xuetao/D-5180-2012 | |
dc.authorwosid | Fujie, Toshinori/O-1493-2018 | |
dc.authorwosid | Kaji, Hirokazu/T-2219-2019 | |
dc.authorwosid | Ramalingam, Murugan/AAV-1702-2020 | |
dc.contributor.author | Ostrovidov, Serge | |
dc.contributor.author | Ramalingam, Murugan | |
dc.contributor.author | Bae, Hojae | |
dc.contributor.author | Orive, Gorka | |
dc.contributor.author | Fujie, Toshinori | |
dc.contributor.author | Shi, Xuetao | |
dc.contributor.author | Kaji, Hirokazu | |
dc.date.accessioned | 2024-07-05T15:24:08Z | |
dc.date.available | 2024-07-05T15:24:08Z | |
dc.date.issued | 2023 | |
dc.department | Atılım University | en_US |
dc.department-temp | [Ostrovidov, Serge; Kaji, Hirokazu] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn IBB, Dept Biomech, Tokyo, Japan; [Ramalingam, Murugan] Dankook Univ, Inst Tissue Regenerat Engn, Cheonan, South Korea; [Ramalingam, Murugan] Dankook Univ, PLUS NBM Global Res Ctr, Dept Nanobiomed Sci, BK21,Regenerat Med Res Ctr, Cheonan, South Korea; [Ramalingam, Murugan] Chengdu Univ, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China; [Bae, Hojae] Konkuk Univ, KU Convergence Sci & Technol Inst, Dept Stem Cell & Regenerat Biotechnol, Hwayang dong,Kwangjin Gu, Seoul, South Korea; [Orive, Gorka] Univ Basque Country UPV, Vitoria-gasteiz, Spain; [Orive, Gorka] Univ Basque Country UPV, Sch Pharm, Lab Pharmaceut, NanoBioCel Grp, Vitoria, Spain; [Orive, Gorka] Biomed Res Networking Ctr Bioengn, Biomat & Nanomed CIBER BBN, Vitoria, Spain; [Fujie, Toshinori] Tokyo Inst Technol, Dept Life Sci & Technol, Yokohama, Japan; [Shi, Xuetao] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou, Guangdong, Peoples R China; [Ramalingam, Murugan] Dankook Univ, Mechanobiol Dent Med Res Ctr, Cheonan, South Korea; [Ramalingam, Murugan] Atilim Univ, Dept Met & Mat Engn, Ankara, Turkey | en_US |
dc.description | Fujie, Toshinori/0000-0003-1417-8670; Kaji, Hirokazu/0000-0003-2566-4172; Ramalingam, Murugan/0000-0001-6498-9792; ostrovidov, serge/0000-0002-4189-8086; bae, hojae/0000-0003-3057-4999 | en_US |
dc.description.abstract | IntroductionWith the advances in skeletal muscle tissue engineering, new platforms have arisen with important applications in biology studies, disease modeling, and drug testing. Current developments highlight the quest for engineering skeletal muscle tissues with higher complexity . These new human skeletal muscle tissue models will be powerful tools for drug discovery and development and disease modeling.Areas coveredThe authors review the latest advances in in vitro models of engineered skeletal muscle tissues used for testing drugs with a focus on the use of four main cell culture techniques: Cell cultures in well plates, in microfluidics, in organoids, and in bioprinted constructs. Additional information is provided on the satellite cell niche.Expert opinionIn recent years, more sophisticated in vitro models of skeletal muscle tissues have been fabricated. Important developments have been made in stem cell research and in the engineering of human skeletal muscle tissue. Some platforms have already started to be used for drug testing, notably those based on the parameters of hypertrophy/atrophy and the contractibility of myotubes. More developments are expected through the use of multicellular types and multi-materials as matrices . The validation and use of these models in drug testing should now increase. | en_US |
dc.description.sponsorship | Japan Society for the Promotion of Science (JSPS) KAKENHI [22K18936, 21K04852]; AMED [JP21gm1310001]; JST Adaptable and Seamless Technology Transfer Program through Target-driven RD [JPMJTM22BD, JPMJTM22BE]; CASIO SCIENCE PROMOTION FOUNDATION; Research Center for Biomedical Engineering at Tokyo Medical and Dental University, Japan; Spanish Ministry of Economy, Industry, and Competitiveness [PID2019-106094RB-I00/AEI]; Grants-in-Aid for Scientific Research [22K18936] Funding Source: KAKEN | en_US |
dc.description.sponsorship | This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Numbers 22K18936 and 21K04852); AMED (Grant Number JP21gm1310001); JST Adaptable and Seamless Technology Transfer Program through Target-driven R&D (Grant Numbers JPMJTM22BD and JPMJTM22BE); CASIO SCIENCE PROMOTION FOUNDATION, and the Research Center for Biomedical Engineering at Tokyo Medical and Dental University, Japan. Furthermore, G Orive thanks the Spanish Ministry of Economy, Industry, and Competitiveness (PID2019-106094RB-I00/AEI/10.13039/501100011033) for their support. | en_US |
dc.identifier.citationcount | 3 | |
dc.identifier.doi | 10.1080/17460441.2023.2160438 | |
dc.identifier.endpage | 63 | en_US |
dc.identifier.issn | 1746-0441 | |
dc.identifier.issn | 1746-045X | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 36535280 | |
dc.identifier.scopus | 2-s2.0-85145288436 | |
dc.identifier.scopusquality | Q1 | |
dc.identifier.startpage | 47 | en_US |
dc.identifier.uri | https://doi.org/10.1080/17460441.2023.2160438 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14411/2397 | |
dc.identifier.volume | 18 | en_US |
dc.identifier.wos | WOS:000903993900001 | |
dc.identifier.wosquality | Q1 | |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.scopus.citedbyCount | 7 | |
dc.subject | Bioprinting | en_US |
dc.subject | drug development | en_US |
dc.subject | drug evaluation | en_US |
dc.subject | microfluidics | en_US |
dc.subject | muscle skeletal | en_US |
dc.subject | organoids | en_US |
dc.subject | stem cells | en_US |
dc.title | Latest Developments in Engineered Skeletal Muscle Tissues for Drug Discovery and Development | en_US |
dc.type | Review | en_US |
dc.wos.citedbyCount | 6 | |
dspace.entity.type | Publication |